Pathophysiological insights into ALS with C9ORF72 expansions
- Kelly L Williams1,2,3,
- Jennifer A Fifita1,2,
- Steve Vucic4,
- Jennifer C Durnall2,
- Matthew C Kiernan5,
- Ian P Blair1,2,3,
- Garth A Nicholson2,3,6
- 1Australian School of Advanced Medicine, Macquarie University, Sydney, New South Wales, Australia
- 2Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, New South Wales, Australia
- 3Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
- 4Department of Neurology, Westmead Hospital, Sydney, New South Wales, Australia
- 5Prince of Wales Medical, Research Institute and Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia
- 6Molecular Medicine Laboratory, Concord Hospital, Concord, New South Wales, Australia
- Correspondence to Dr Ian P Blair, Australian School of Advanced Medicine, Macquarie University, 2 Technology Place, Sydney, NSW 2109, Australia;
- Received 5 November 2012
- Revised 5 February 2013
- Accepted 9 February 2013
- Published Online First 5 March 2013
Objective Expansions of a hexanucleotide repeat in C9ORF72 are a common cause of familial amyotrophic lateral sclerosis (ALS) and a small proportion of sporadic ALS cases. We sought to examine clinical and neurophysiological features of familial and sporadic ALS with C9ORF72 expansions.
Methods C9ORF72 was screened for expansions in familial and sporadic ALS. Clinical features of expansion positive cases are described. Cortical excitability studies used novel threshold tracking transcranal magnetic stimulation techniques with motor evoked responses recorded over the abductor pollicis brevis.
Results and conclusions Analysis of large clinical cohorts identified C9ORF72 expansions in 38.5% (72/187) of ALS families and 3.5% (21/606) of sporadic ALS cases. Two expansion positive families were known to carry reported ANG mutations, possibly implicating an oligogenic model of ALS. 6% of familial ALS cases with C9ORF72 expansions were also diagnosed with dementia. The penetrance of ALS was 50% at age 58 years in male subjects and 63 years in female subjects. 100% penetrance of ALS was observed in male subjects by 86 years, while 6% of female subjects remained asymptomatic at age 82 years. Gender specific differences in age of onset were evident, with male subjects significantly more likely to develop ALS at a younger age. Importantly, features of cortical hyperexcitability were apparent in C9ORF72-linked familial ALS as demonstrated by significant reduction in short interval intracortical inhibition and cortical silent period duration along with an increase in intracortical facilitation and motor evoked potential amplitude, indicating that cortical hyperexcitability is an intrinsic process in C9ORF72-linked ALS.